Celyad Oncology SA
F:1C0

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
F:1C0
Watchlist
Price: 0.1435 EUR 10.38%
Market Cap: 1.7m EUR

Celyad Oncology SA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celyad Oncology SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Celyad Oncology SA
XBRU:CYAD
Operating Income
-€6.4m
CAGR 3-Years
37%
CAGR 5-Years
26%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Operating Income
-$24.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Galapagos NV
AEX:GLPG
Operating Income
-€320m
CAGR 3-Years
-48%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Operating Income
€901k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
European Medical Solutions
XBRU:ALEMS
Operating Income
€1.3m
CAGR 3-Years
251%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
1.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

1C0 Intrinsic Value
0.0312 EUR
Overvaluation 78%
Intrinsic Value
Price

See Also

What is Celyad Oncology SA's Operating Income?
Operating Income
-6.4m EUR

Based on the financial report for Jun 30, 2025, Celyad Oncology SA's Operating Income amounts to -6.4m EUR.

What is Celyad Oncology SA's Operating Income growth rate?
Operating Income CAGR 5Y
26%

Over the last year, the Operating Income growth was 17%. The average annual Operating Income growth rates for Celyad Oncology SA have been 37% over the past three years , 26% over the past five years .

Back to Top